UNSPSC 51332525: Pipamperone dihydrochloride

This classification denotes an anxiolytic with the molecular formula C21H30FN3O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IT085U64JB, chemically known as 1'-(3-(p-fluorobenzoyl)propyl)-(1,4'-bipiperidine)-4'-carboxamide dihydrochloride, but more generally known as pipamperone dihydrochloride, which bears US NIH Compound Identifier 17139. European Medicines Agency schedules pipamperone dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09860MIG.

Most nations, for tariff purposes, schedule pipamperone dihydrochloride under HS 29333999. SMILES: C1CC(CCC1C(=O)CCCN2CCC(CC2)(C(=O)N)N3CCCCC3)F.CL.CL.

UNSPSC 51332525 Pipamperone dihydrochloride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally covers a specific pharmaceutical active ingredient, but the three recent opportunities tagged to it involve naloxone procurement, therapeutic pharmacy program design, and generic multi-source pharmaceutical distribution agreements—none of which concern pipamperone specifically. The mismatch between the code's scope and the work actually being solicited suggests that this code receives little relevant activity in state and local contracting, or that issuers are applying it as a catch-all for pharmaceutical-related opportunities without regard to the active-ingredient specificity the code implies.

The three opportunities show fragmented issuing-body participation: Seminole County, Florida (an IFB for naloxone and drug deactivation systems posted June 30, 2026, due July 26, 2023); the Texas Health and Human Services Commission (an RFI for therapeutic pharmacy program capabilities, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance through the Minnesota Department of Administration (an RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, due March 26, 2026). The geographic spread spans Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving Oregon as well. No opportunities explicitly mention pipamperone, and the code shows no pattern of recent state and local activity that would support pipamperone-specific market development.